Opiant Pharmaceuticals (OPNT) Cash Flow Statement

Click line-items for a historical chart and %

Net income	7.65M
Depreciation and amortization	3.86M
Provision for losses on accounts receivable	79K
Deferred income taxes	-902K
Non-cash stock-based compensation expense	2.37M
Non-cash accretion of market discount on marketable securities	-16K
Loss on disposition of fixed assets	1K
Accounts receivable	-335K
Inventory	494K
Prepaid expenses and other current assets	-2.03M
Other assets	-11K
Accounts payable	393K
Accrued liabilities	-1.14M
Accrued income taxes	-3.95M
Deferred revenue	-3.71M
Deferred rent	913K
Excess tax benefit from exercise of stock options	-1.42M
Net cash provided by operating activities	2.24M
Purchase of property and equipment	-5.01M
Purchase of marketable securities	-19.87M
Proceeds from sale/maturity of marketable securities	19M
Net cash used in investing activities	-16.7M
Acquisition of treasury stock	-133K
Proceeds from exercise of common stock options	1.77M
Excess tax benefit from exercise of stock options	1.42M
Payment of dividends to stockholders	-6.92M
Net cash (used in) provided by financing activities	-2.91M
Effect of exchange rate changes on cash and cash equivalents	-255K
Net increase (decrease) in cash and cash equivalents	-17.62M
Cash and cash equivalents, beginning of period	72.36M
Cash and cash equivalents, end of period	54.74M

Entities mentioned with OPNT

View All Entities